Imprivata upgrades OneSign biometric application security, partners with Modeus

Imprivata has unveiled OneSign 7.0 with Imprivata Web SSO for seamless, more secure fingerprint biometric access to on-premise and cloud applications in hybrid environments pertaining to healthcare organizations, the company announced.

OneSign 7.0 is the company’s most recent version of its authentication and access management solution which can be accessed from any device including mobile devices, personal laptops, and virtual desktops. The integration with Web SSO delivers passwordless authentication for devices in the workspace.

Imprivata Web SSO facilitates the integration of cloud applications from the Microsoft Azure Marketplace and offers multifactor authentication, including push token notification, to ensure compliance and fend off unauthorized cloud access. Multifactor authentication options are compliant with DEA requirements for electronic prescribing for controlled substances (EPCS).

“Healthcare is becoming a hybrid environment. The continuing adoption of cloud applications in conjunction with on-prem applications and systems is trending healthcare infrastructures towards a hybrid state. That shift coupled with the increasingly distributed workforce continues to contribute to the erosion of the once well-defined IT security perimeter,” said Gus Malezis, CEO at Imprivata. “To support the adoption of cloud technology without disrupting user experience or the delivery of patient care, we continue to evolve our solutions to deliver secure, frictionless access to all applications, regardless of whether they are on-prem or in the cloud.”

Imprivata has also entered a strategic partnership with Australian software company Modeus to integrate Imprivata Confirm ID with HS8, a hospital-wide controlled drug platform. As a result, users will use biometric fingerprint authentication or card tap to confirm register entries, removing the need for manually typing in usernames and passwords. The partnership will also increase patient safety by offering re-authentication for hospital medication transactions such as stock checks, stock transfers, and receipt of stock, as well as dispensing from pharmacy, ward, and theatre areas, the company says.

Earlier in November, Imprivata was chosen by Sentara Healthcare to deliver its biometric palm vein identity authentication for over 750,000 patients.

Article Topics

access management  |  biometrics  |  fingerprint authentication  |  healthcare  |  Imprivata